Rigel Pharmaceuticals | RIGL - Operating Profit

Stock Price
29.48
Daily Change
-0.15 -0.51%
Monthly
-13.68%
Yearly
49.64%
Q1 Forecast
33.68

Rigel Pharmaceuticals reported $14.06M in Operating Profit for its fiscal quarter ending in September of 2024.





Operating Profit Change Date
Agenus USD -13.31M 12.58M Mar/2025
Amgen USD 3.96B 464M Dec/2025
Anika Therapeutics USD -4.28M 32.1M Mar/2025
Arrowhead Research USD 40.81M 3.3M Dec/2025
AstraZeneca USD 2.97B 4.48B Dec/2025
BioMarin Pharmaceutical USD 198.39M 230.08M Dec/2025
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Celldex Therapeutics USD -87.15M 13.54M Dec/2025
Daiichi Sankyo JPY 89.54B 42.01B Dec/2025
Eli Lilly USD 8.99B 599.9M Dec/2025
Halozyme Therapeutics USD -88.41M 306.33M Dec/2025
Heron Therapeutics USD -5.66M 782K Sep/2024
Intrexon USD -60.84M 26.62M Jun/2024
Ionis Pharmaceuticals USD -215M 54.82M Dec/2025
Karyopharm Therapeutics USD -31.28M 5M Dec/2024
Ligand Pharmaceuticals USD 158.89M 149.17M Sep/2025
MacroGenics USD 18.64M 55.4M Sep/2025
Neurocrine Biosciences USD 227.9M 11.4M Dec/2025
Pfizer USD 4.65B 3.99B Dec/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Rigel Pharmaceuticals USD 14.06M 13.61M Sep/2024
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Ultragenyx Pharmaceutical USD -114M 56.89M Dec/2025
Veracyte USD 24.63M 1.52M Dec/2025